OS Cancer Research Results

OS, overall survival: Click to Expand ⟱
Source:
Type:
Overall survival
Scientific Papers found: Click to Expand⟱
2027- PB,    Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors
- Trial, Var, NA
TumCG↓, Dose↝, toxicity↓, Dose↝, HDAC↓, OS↑,
1672- PBG,    The Potential Use of Propolis as an Adjunctive Therapy in Breast Cancers
- Review, BC, NA
ChemoSen↓, RadioS↑, Inflam↓, AntiCan↑, Dose∅, mtDam↑, Apoptosis?, OCR↓, ATP↓, ROS↑, ROS↑, LDH↓, TP53↓, Casp3↓, BAX↓, P21↓, ROS↑, eNOS↑, iNOS↑, eff↑, hTERT/TERT↓, cycD1/CCND1↓, eff↑, eff↑, eff↑, eff↑, STAT3↓, TIMP1↓, IL4↓, IL10↓, OS↑, Dose∅, ER Stress↑, ROS↑, NF-kB↓, p65↓, MMP↓, TumAuto↑, LC3II↑, p62↓, TLR4↓, mtDam↑, LDH↓, ROS↑, Glycolysis↓, HK2↓, PFK↓, PKM2↓, LDH↓, IL10↓, HDAC8↓, eff↑, eff↑, P21↑,
1673- PBG,    An Insight into Anticancer Effect of Propolis and Its Constituents: A Review of Molecular Mechanisms
- Review, Var, NA
TumCP↓, Apoptosis↑, TumCCA↑, MALAT1↓, P53↑, RadioS↑, OS↑, ROS↑, NF-kB↓, p65↑, MMP↓, ROS↑, MMP9↓, β-catenin/ZEB1↓, Vim↓, E-cadherin↓, VEGF↓, EMT↓,
4948- PEITC,    Sensory acceptable equivalent doses of β-phenylethyl isothiocyanate (PEITC) induce cell cycle arrest and retard the growth of p53 mutated oral cancer in vitro and in vivo
- vitro+vivo, Oral, CAL27 - vitro+vivo, Oral, FaDu - vitro+vivo, Oral, SCC4 - vitro+vivo, Oral, SCC9
TumCD↑, TumCG↓, OS↑, ROS↑, P53↑, P21↑, TumCCA↑, Ki-67↓,
4954- PEITC,    Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate
- vitro+vivo, Ovarian, SKOV3
ROS↑, GSH↓, selectivity↑, mtDam↑, TumCD↑, OS↑, eff↑, *toxicity↓, H2O2↑, NO↑, eff↓, GPx↓, Dose↝, eff↑,
4963- PEITC,    Sensory Acceptable Equivalent Doses of β - Phenylethyl isothiocyanate (PEITC) Induce Cell Cycle Arrest and Retard Growth of p53 Mutated Oral Cancer In Vitro and In Vivo
- vitro+vivo, Oral, CAL27 - vitro+vivo, Oral, FaDu - vitro+vivo, Oral, SCC4 - vitro+vivo, Oral, SCC9
Dose↝, selectivity↑, TumCG↓, OS↑, ROS↑, P53↑, P21↑, TumCCA↑, Ki-67↓,
4924- PEITC,    Nutri-PEITC Jelly Significantly Improves Progression-Free Survival and Quality of Life in Patients with Advanced Oral and Oropharyngeal Cancer: A Blinded Randomized Placebo-Controlled Trial
- Trial, Oral, NA
QoL↑, P53↑, OS↑, Cyt‑c↝, other↝, ROS↑, selectivity↑, P21↑, TumCCA↑, Dose↝, BioAv↑, Weight↑, chemoP↑,
5216- PI,  doxoR,    Piperine enhances doxorubicin sensitivity in triple-negative breast cancer by targeting the PI3K/Akt/mTOR pathway and cancer stem cells
- vitro+vivo, BC, MDA-MB-231
ChemoSen↑, necrosis↑, PTEN↓, PI3K↓, p‑Akt↓, mTOR↓, ALDH↓, TumVol↓, OS↑, cardioP↑, cl‑PARP↑,
3587- PI,    Piperine: A review of its biological effects
- Review, Park, NA - Review, AD, NA
*hepatoP↑, *Inflam↓, *neuroP↑, *antiOx↑, *angioG↑, *cardioP↑, *BioAv↑, *P450↓, *eff↑, *BioAv↑, E-cadherin↓, ER(estro)↓, MMP2↓, MMP9↓, VEGF↓, cMyc↓, BAX↑, P53↑, TumCG↓, OS↑, *cognitive↑, *GSK‐3β↓, *GSH↑, *Casp3↓, *Casp9↓, *Cyt‑c↓, *lipid-P↓, *motorD↑, *AChE↓, *memory↑, *cardioP↑, *ROS↓, *PPARγ↑, *ALAT↓, *AST↓, *ALP↓, *AMPK↑, *5HT↑, *SIRT1↑, *eff↑,
2942- PL,    Piperlongumine increases sensitivity of colorectal cancer cells to radiation: Involvement of ROS production via dual inhibition of glutathione and thioredoxin systems
- in-vitro, CRC, CT26 - in-vitro, CRC, DLD1 - in-vivo, CRC, CT26
ROS↑, GSH↓, TrxR↓, RadioS↑, DNAdam↑, TumCCA↑, mitResp↓, GSTs↓, OS↑,
2303- QC,  doxoR,    Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells
- in-vitro, BC, 4T1 - in-vivo, NA, NA
cardioP↑, hepatoP↑, TumCG↓, OS↑, ChemoSen↑, chemoP↑, Hif1a↓, *Hif1a↑, selectivity↑, TumVol↓, OS↑,
3352- QC,    A review of quercetin: Antioxidant and anticancer properties
- Review, Var, NA
*antiOx↑, *lipid-P↓, *TNF-α↓, *NF-kB↓, *COX2↓, *IronCh↑, P53↓, TumCCA↑, HSPs↓, P21↓, RAS↓, ER(estro)↑, OS?,
5969- Rad,  CET,    Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
- Trial, HNSCC, NA
Dose↝, radioP↑, OS↑,
5971- Rad,  CET,    Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
- Trial, HNSCC, NA
OS↑,
5286- Ramu,    Ramucirumab efficacy in first-line gastric and esophageal cancer treatment
- Review, GC, NA
VEGFR2↓, OS↑, toxicity↝,
5284- Ramu,    https://pmc.ncbi.nlm.nih.gov/articles/PMC4131847/
- Review, Var, NA
VEGFR2↓, OS↑, angioG↓, toxicity↝, ChemoSen↑, Dose↝,
5285- Ramu,  docx,    A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
- Trial, NSCLC, NA
OS↑,
5287- Ramu,    Real-Life Use of Ramucirumab in Gastric Cancer in Spain: the RAMIS Study
- in-vivo, GC, NA
VEGFR2↓, OS↑, OS↑,
2990- RES,    Resveratrol reduces cerebral edema through inhibition of de novo SUR1 expression induced after focal ischemia
- in-vivo, Stroke, NA
*OS↑, *antiOx↑, Sp1/3/4↓,
3490- RF,    Multidimensional insights into the repeated electromagnetic field stimulation and biosystems interaction in aging and age-related diseases
- Review, AD, NA - Review, Park, NA
*OS↑, *memory↑, *cognitive↑, *memory↑, *Aβ↓, *eff↑, *HSF1↑, *HSP70/HSPA5↑,
5138- SAS,  Rad,    Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion
- vitro+vivo, GBM, NA
cystine↓, GSH↓, ROS↑, RadioS↑, eff↓, DNAdam↑, OS↑,
5036- SAS,    Targeting xCT with sulfasalazine suppresses triple-negative breast cancer growth via inducing autophagy and coordinating cell cycle and proliferation
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
xCT↓, GSH↓, OS↑, Myc↓, CDK1↓, CD44↓, eff↑, TumCG↓,
5035- SAS,    Sulfasalazine, a potent suppressor of gastric cancer proliferation and metastasis by inhibition of xCT: Conventional drug in new use
- Human, GC, NA - in-vitro, GC, NCI-N87 - in-vitro, GC, SGC-7901
other?, TumCP↓, TumMeta↓, TumCI↓, xCT↓, OS↑,
1696- Se,    Selenium dietary intake and survival among CRC patients
- Human, CRC, NA
OS↑,
1689- Se,    Selenium and breast cancer - An update of clinical and epidemiological data
- Analysis, BC, NA
OS↑, eff↑, Dose∅, *toxicity↝, eff↑,
1705- Se,    Serum Selenium Level and 10-Year Survival after Melanoma
- Study, Melanoma, NA
OS↑,
4492- Se,    Selenium in cancer prevention: a review of the evidence and mechanism of action
- Review, Var, NA
Risk↓, AntiCan↑, *selenoP↑, TumMeta↓, *DNAdam↓, OS↑, *ROS↓,
4496- Se,    Selenium status and survival from colorectal cancer in the European prospective investigation of cancer and nutrition
- Analysis, CRC, NA
Risk↝, OS↑,
4722- Se,    The Yin and Yang of Nrf2-Regulated Selenoproteins in Carcinogenesis
- Review, Var, NA
Risk↓, *NRF2↓, NRF2↑, *NRF2↓, OS↑, eff↝, eff↝, NRF2↝,
3947- Shank,    Convolvulus pluricaulis (Shankhapushpi) ameliorates human microtubule-associated protein tau (hMAPτ) induced neurotoxicity in Alzheimer's disease Drosophila model
- in-vivo, AD, NA
*OS↑, *antiOx↑, *ROS↓, *AChE↑, *neuroP↑, *memory↑,
4204- SIL,    Silymarin administration after cerebral ischemia improves survival of obese mice by increasing cortical BDNF and IGF1 levels
- NA, Stroke, NA
*OS↑, *BDNF↑, *IGF-1↑,
3321- SIL,    Silymarin (Milk thistle)
- Review, AD, NA
*neuroP↝, *Dose↝, *Half-Life?, *BioAv↝, *cognitive↑, *Aβ↓, *Inflam↓, *OS↑, *memory↑,
3292- SIL,  Fe,    Anti-tumor activity of silymarin nanoliposomes in combination with iron: In vitro and in vivo study
- in-vitro, BC, 4T1 - in-vivo, BC, 4T1
*antiOx↑, ROS↑, OS↑, Weight↑, TumVol↓, eff↑, Fenton↑,
2233- SK,    Clinical trial on the effects of shikonin mixture on later stage lung cancer
- Trial, Lung, NA
TumVol↓, Remission↑, OS↑, QoL↑, Weight↑, *toxicity∅,
2232- SK,    Shikonin Induces Autophagy and Apoptosis in Esophageal Cancer EC9706 Cells by Regulating the AMPK/mTOR/ULK Axis
- in-vitro, ESCC, EC9706
tumCV↓, TumCMig↓, TumCI↓, TumAuto↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑PARP↑, AMPK↑, mTOR↑, TumVol↓, OS↑, LC3I↑,
2222- SK,    The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis
- in-vitro, OS, U2OS - in-vitro, OS, 143B - in-vivo, NA, NA
Necroptosis↑, RIP1↑, RIP3↑, OS↑, P53↑,
1068- SM,    Danshen Improves Survival of Patients With Breast Cancer and Dihydroisotanshinone I Induces Ferroptosis and Apoptosis of Breast Cancer Cells
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vivo, BC, NA - Human, BC, NA
TumCG↓, Ferroptosis↑, GPx4↓, TumVol↓, OS↑, GSH/GSSG↓,
4895- Sper,    Spermidine as a target for cancer therapy
- Review, Var, NA - Review, AD, NA
TumAuto↑, Apoptosis↑, OS↑, CRM↑, TumCG⇅, cardioP↑, cognitive↑, *Dose⇅,
1707- SSE,    A Diet Lacking Selenium, but Not Zinc, Copper or Manganese, Induces Anticancer Activity in Mice with Metastatic Cancers
- in-vivo, Ovarian, NA - in-vivo, BC, NA
OS↓,
5078- SSE,  Rad,    Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer
- Trial, Pca, NA
Half-Life↝, OS↑, Pain↓, PSA↓, GSH↓, ROS↑, selectivity↑, TumCG↓, AR↓, Dose↑, ChemoSen↑, RadioS↑,
5084- SSE,  GEM,    The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro and In Vivo Study
- in-vitro, PC, PANC1 - vitro+vivo, PC, Panc02
tumCV↓, ChemoSen↑, TumCG↓, OS↑, MMP↓, AIF↑, GSH↓, Trx↓, ROS↑, AntiTum↑,
4494- SSE,    Advances in the study of selenium and human intestinal bacteria
- Review, IBD, NA - Review, Var, NA
*Risk↓, OS↑, *CRP↓, *GPx↑, *Inflam↓, *ROS↓, *GutMicro↑, *selenoP↑, *other↓,
2131- TQ,    Therapeutic impact of thymoquninone to alleviate ischemic brain injury via Nrf2/HO-1 pathway
- in-vitro, Stroke, NA - in-vivo, Nor, NA
*eff↑, *OS↑, *Inflam↓, *ROS↓, *NRF2↑, *HO-1↑,
3420- TQ,    Thymoquinone alleviates the accumulation of ROS and pyroptosis and promotes perforator skin flap survival through SIRT1/NF-κB pathway
- in-vitro, Nor, HUVECs - in-vitro, NA, NA
*NF-kB↓, *NLRP3↓, *angioG↑, *MMP9↑, *VEGF↑, *OS↑, *Pyro?, *ROS↓, *Apoptosis↓, *SIRT1↑, *SOD1↑, *HO-1↑, *eNOS↑, *ASC?, *Casp1↓, *IL1β↓, *IL18↓,
2412- TTT,    A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights
- Review, GBM, NA
TumCG↓, eff↝, OS↑,
4863- Uro,    Urolithin A reduces amyloid-beta load and improves cognitive deficits uncorrelated with plaque burden in a mouse model of Alzheimer's disease
- in-vivo, AD, NA
*memory↑, *Aβ↓, *OS↑, *cognitive↑,
4875- Uro,    Impact of the Natural Compound Urolithin A on Health, Disease, and Aging
- Review, AD, NA - Review, Stroke, NA - Review, ostP, NA - Review, IBD, NA
*MitoP↓, *Strength↑, *PINK1↑, *PARK2↑, *Inflam↓, *COX2↓, *IL1β↓, *IL6↓, *TNF-α↓, *OS↑, *cardioP↑, *memory↑, *neuroG↑, *neuroP↑, *Cartilage↑, *Inflam↓, *RenoP↑, *eff↑, *Dose↝, *Half-Life↑, *NRF2↑, *GutMicro↑,
4853- Uro,    Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer
- vitro+vivo, PC, MIA PaCa-2 - in-vitro, NA, PANC1
p‑Akt↓, p‑p70S6↓, TumCG↓, OS↑, PI3K↓, mTOR↓, TumCP↓, TumCMig↓, Apoptosis↑, TAMS↓, Treg lymp↓, Wnt↓, IGF-1↓, *toxicity↓, *BioAv↑, Half-Life↝,
4311- VitB1/Thiamine,    Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy
- in-vivo, AD, NA
*Aβ↓, *p‑tau↓, *ROS↓, *cognitive↑, *OS↑, *Mood↑, *neuroP↑, *Inflam↓, *NRF2↑, *PGC-1α↑, *AGEs↓, *4-HNE↓, *NQO1↑, *COX2↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *GSK‐3β↓,
615- VitC,    High Dose IV Vitamin C and Metastatic Breast Cancer: A Case Report
- Case Report, NA, NA
OS↑, Remission↑,

Showing Research Papers: 201 to 250 of 263
Prev Page 5 of 6 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 263

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

cystine↓, 1,   Fenton↑, 1,   Ferroptosis↑, 1,   GPx↓, 1,   GPx4↓, 1,   GSH↓, 6,   GSH/GSSG↓, 1,   GSTs↓, 1,   H2O2↑, 1,   NRF2↑, 1,   NRF2↝, 1,   ROS↑, 16,   Trx↓, 1,   TrxR↓, 1,   xCT↓, 2,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   ATP↓, 1,   mitResp↓, 1,   MMP↓, 3,   mtDam↑, 3,   OCR↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   cMyc↓, 1,   CRM↑, 1,   Glycolysis↓, 1,   HK2↓, 1,   LDH↓, 3,   PFK↓, 1,   PKM2↓, 1,  

Cell Death ⓘ

p‑Akt↓, 2,   Apoptosis?, 1,   Apoptosis↑, 4,   BAX↓, 1,   BAX↑, 2,   Bcl-2↓, 1,   Casp3↓, 1,   cl‑Casp3↑, 1,   cl‑Casp8↑, 1,   Cyt‑c↝, 1,   Ferroptosis↑, 1,   hTERT/TERT↓, 1,   iNOS↑, 1,   Myc↓, 1,   Necroptosis↑, 1,   necrosis↑, 1,   RIP1↑, 1,   TumCD↑, 2,  

Kinase & Signal Transduction ⓘ

p‑p70S6↓, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

other?, 1,   other↝, 1,   tumCV↓, 2,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,   HSPs↓, 1,  

Autophagy & Lysosomes ⓘ

LC3I↑, 1,   LC3II↑, 1,   p62↓, 1,   TumAuto↑, 3,  

DNA Damage & Repair ⓘ

DNAdam↑, 2,   P53↓, 1,   P53↑, 6,   cl‑PARP↑, 2,   TP53↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   cycD1/CCND1↓, 1,   P21↓, 2,   P21↑, 4,   TumCCA↑, 6,  

Proliferation, Differentiation & Cell State ⓘ

ALDH↓, 1,   CD44↓, 1,   EMT↓, 1,   HDAC↓, 1,   HDAC8↓, 1,   IGF-1↓, 1,   mTOR↓, 2,   mTOR↑, 1,   PI3K↓, 2,   PTEN↓, 1,   RAS↓, 1,   STAT3↓, 1,   TumCG↓, 11,   TumCG⇅, 1,   Wnt↓, 1,  

Migration ⓘ

E-cadherin↓, 2,   Ki-67↓, 2,   MALAT1↓, 1,   MMP2↓, 1,   MMP9↓, 2,   RIP3↑, 1,   TIMP1↓, 1,   Treg lymp↓, 1,   TumCI↓, 2,   TumCMig↓, 2,   TumCP↓, 3,   TumMeta↓, 2,   Vim↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   eNOS↑, 1,   Hif1a↓, 1,   NO↑, 1,   TAMS↓, 1,   VEGF↓, 2,   VEGFR2↓, 3,  

Immune & Inflammatory Signaling ⓘ

IL10↓, 2,   IL4↓, 1,   Inflam↓, 1,   NF-kB↓, 2,   p65↓, 1,   p65↑, 1,   PSA↓, 1,   TLR4↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,   ER(estro)↓, 1,   ER(estro)↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   ChemoSen↓, 1,   ChemoSen↑, 5,   Dose↑, 1,   Dose↝, 7,   Dose∅, 3,   eff↓, 2,   eff↑, 13,   eff↝, 3,   Half-Life↝, 2,   RadioS↑, 5,   selectivity↑, 5,  

Clinical Biomarkers ⓘ

AR↓, 1,   hTERT/TERT↓, 1,   Ki-67↓, 2,   LDH↓, 3,   Myc↓, 1,   PSA↓, 1,   TP53↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   AntiTum↑, 1,   cardioP↑, 3,   chemoP↑, 2,   cognitive↑, 1,   hepatoP↑, 1,   OS?, 1,   OS↓, 1,   OS↑, 40,   Pain↓, 1,   QoL↑, 2,   radioP↑, 1,   Remission↑, 2,   Risk↓, 2,   Risk↝, 1,   toxicity↓, 1,   toxicity↝, 2,   TumVol↓, 6,   Weight↑, 3,  
Total Targets: 153

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

4-HNE↓, 1,   antiOx↑, 5,   GPx↑, 1,   GSH↑, 1,   HO-1↑, 2,   lipid-P↓, 2,   NQO1↑, 1,   NRF2↓, 2,   NRF2↑, 3,   PARK2↑, 1,   ROS↓, 7,   selenoP↑, 2,   SOD1↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

PGC-1α↑, 1,   PINK1↑, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   AMPK↑, 1,   PPARγ↑, 1,   SIRT1↑, 2,  

Cell Death ⓘ

Apoptosis↓, 1,   Casp1↓, 1,   Casp3↓, 1,   Casp9↓, 1,   Cyt‑c↓, 1,   Pyro?, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,  

Protein Folding & ER Stress ⓘ

HSF1↑, 1,   HSP70/HSPA5↑, 1,  

Autophagy & Lysosomes ⓘ

MitoP↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

GSK‐3β↓, 2,   IGF-1↑, 1,   neuroG↑, 1,  

Migration ⓘ

Cartilage↑, 1,   MMP9↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↑, 2,   eNOS↑, 1,   Hif1a↑, 1,   VEGF↑, 1,  

Immune & Inflammatory Signaling ⓘ

ASC?, 1,   COX2↓, 3,   CRP↓, 1,   IL18↓, 1,   IL1β↓, 3,   IL6↓, 1,   Inflam↓, 7,   NF-kB↓, 3,   TNF-α↓, 3,  

Synaptic & Neurotransmission ⓘ

5HT↑, 1,   AChE↓, 1,   AChE↑, 1,   BDNF↑, 1,   p‑tau↓, 1,  

Protein Aggregation ⓘ

AGEs↓, 1,   Aβ↓, 4,   NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 3,   BioAv↝, 1,   Dose⇅, 1,   Dose↝, 2,   eff↑, 5,   Half-Life?, 1,   Half-Life↑, 1,   P450↓, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   CRP↓, 1,   GutMicro↑, 2,   IL6↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 3,   cognitive↑, 5,   hepatoP↑, 1,   memory↑, 7,   Mood↑, 1,   motorD↑, 1,   neuroP↑, 4,   neuroP↝, 1,   OS↑, 10,   RenoP↑, 1,   Risk↓, 1,   Strength↑, 1,   toxicity↓, 2,   toxicity↝, 1,   toxicity∅, 1,  
Total Targets: 86

Scientific Paper Hit Count for: OS, overall survival
17 Magnetic Fields
15 Chemotherapy
15 Magnetic Field Rotating
14 Vitamin C (Ascorbic Acid)
13 Hydrogen Gas
10 Radiotherapy/Radiation
9 diet Methionine-Restricted Diet
8 Silver-NanoParticles
8 immunotherapy
8 beta-glucans
7 diet Plant based
7 Selenium
6 Alpha-Lipoic-Acid
6 Curcumin
6 Dichloroacetate
5 HydroxyCitric Acid
5 cetuximab
5 diet FMD Fasting Mimicking Diet
5 Melatonin
5 Bicarbonate(Sodium)
5 Phenylbutyrate
4 Bevacizumab (brand Avastin)
4 EGCG (Epigallocatechin Gallate)
4 capecitabine
4 Phenethyl isothiocyanate
4 Ramucirumab (CYRAMZA)
4 Selenite (Sodium)
3 3-bromopyruvate
3 almonertinib
3 Anti-oxidants
3 Aspirin -acetylsalicylic acid
3 Arsenic trioxide
3 Atorvastatin
3 Gemcitabine (Gemzar)
3 Carvacrol
3 Oxygen, Hyperbaric
3 Exercise
3 diet Short Term Fasting
3 metronomic chemo
3 nicotinamide adenine dinucleotide
3 Sulfasalazine
3 Silymarin (Milk Thistle) silibinin
3 Shikonin
3 Urolithin
2 Lycopene
2 low dose naltrexone
2 Acetyl-l-carnitine
2 Apigenin (mainly Parsley)
2 Ashwagandha(Withaferin A)
2 Bufalin/Huachansu
2 Bifidobacterium
2 Docetaxel
2 Chlorogenic acid
2 Citric Acid
2 Calorie Restriction Mimetics
2 Resveratrol
2 Spermidine
2 Sulforaphane (mainly Broccoli)
2 Disulfiram
2 Orlistat
2 Honokiol
2 itraconazole
2 Juglone
2 Metformin
2 Propolis -bee glue
2 Piperine
2 doxorubicin
2 Quercetin
2 Thymoquinone
2 VitK3,menadione
1 2-DeoxyGlucose
1 Auranofin
1 Astragalus
1 Hyperthermia
1 Akkermansia
1 Baicalein
1 Berberine
1 Brucea javanica
1 Bacopa monnieri
1 Boron
1 Butyrate
1 Caffeine
1 Caffeic Acid Phenethyl Ester (CAPE)
1 Sorafenib (brand name Nexavar)
1 Cannabidiol
1 Celastrol
1 chitosan
1 Chocolate
1 Choline
1 Chrysin
1 Hydroxycinnamic-acid
1 Artemisinin
1 salinomycin
1 Deguelin
1 diet Fermented Foods
1 Bortezomib
1 diet Ketogenic
1 Copper and Cu NanoParticles
1 Emodin
1 Electrical Pulses
1 Garcinol
1 hydroxychloroquine
1 mebendazole
1 nivolumab
1 Magnesium
1 Naringin
1 Noscapine
1 Piperlongumine
1 Radio Frequency
1 Shankhpushpi
1 Iron
1 Salvia miltiorrhiza
1 Tumor Treating Fields
1 Vitamin B1/Thiamine
1 Vitamin K2
1 Xylitol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:229  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page